TABLE 5.

Generalized Linear Models Evaluating Association Between MACE-Related^a Health Care Costs of First MACE and Measures of Interest Among Patients with a MACE

Measures of Interest, Each from a Separate Model b	Rate Ratio c	95% CI	P Value	Sample Size
At least aged 60 years at index (reference = under 60)	0.366	(0.328-0.408)	< 0.001	2,503
Pre-index diabetes (reference = no diabetes)	0.960	(0.866-1.064)	0.437	2,503
Pre-index renal disease (reference = no renal disease)	2.684	(0.588-12.247)	0.203	2,503
Statin use at end of index episode (reference = no statin use)	0.908	(0.828-0.996)	0.041	2,503
Early MACE within 3 months (reference = after 3 months)	1.355	(1.237-1.484)	< 0.001	2,503
STEMI index MI event (reference = NSTEMI)	0.994	(0.876-1.129)	0.931	1,610

^a MACE-related services were identified as those with a MACE diagnosis, an SCE diagnosis or procedure, or a CVD drug prescription.

^b Each model additionally controls for baseline age, sex, geographic (census) region, health plan type, presence of pre-index flagged conditions, pre-index CCI score, and statin use prior to post-index follow-up unless collinear with independent variable of interest.

^c The rate ratio is the exponentiated parameter estimate, denoting the multiplicative effect of the reported level versus the reference level.

CCI = Charlson Comorbidity Index; CI = confidence interval; CVD = cardiovascular disease; MACE = major adverse cardiovascular event; MI = myocardial infarction; NSTEMI = non-ST-elevation myocardial infarction; SCE = secondary coronary event; STEMI = ST-elevation myocardial infarction.